| Outcome Measures: |
Primary: Left Ventricular (LV) mass Changes, Changes in Left Ventricular (LV) mass (indexed to BSA) at 6 months in patients with Type 2 diabetes who receive empagliflozin vs. placebo. This will be measured using CMRI., 6 months | Secondary: LV end-diastolic volume, Changes in LV end-diastolic volume (indexed to BSA) at baseline and at 6 months in patients with type 2 diabetes treated with empagliflozin. This will be measured using CMRI., 6 months|End-systolic volume (indexed to BSA), Changes in end-systolic volume (indexed to BSA) at baseline and at 6 months in patients with type 2 diabetes treated with empagliflozin. This will be measured using CMRI., 6 months|Left Ventricular Ejection Fraction (LVEF), Changes LVEF at baseline and at 6 months in patients with type 2 diabetes treated with empagliflozin. This will be measured using CMRI., 6 months|Regional LV diastolic function, Changes in Regional LV diastolic function at baseline and at 6 months in patients with type 2 diabetes treated with empagliflozin. This will be measured using CMRI., 6 months|Regional LV systolic function, Changes in Regional LV systolic function at baseline and at 6 months in patients with type 2 diabetes treated with empagliflozin. This will be measured using CMRI., 6 months|Aortic pulse wave velocity and distensibility, Changes in aortic pulse wave velocity and distensibility (as arterial stiffness) at baseline and at 6 months in patients with type 2 diabetes treated with empagliflozin., 6 months|Biomarkers, Changes on a panel of biomarkers involved in the pathophysiology of heart failure at baseline, 1 months and 6 months, in patients with type 2 diabetes treated with empagliflozin., 6 months|Plasma catecholamine levels, Changes in plasma catecholamine levels at baseline, 1 months and 6 months, in patients with type 2 diabetes treated with empagliflozin., 6 months
|
